 SEATTLE, Jan. 10, 2022 GLOBE NEWSWIRE -- Neoleukin Therapeutics, Inc., Neoleukin NASDAQ:NLTX, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022. The on-demand presentation will be available beginning at 7:00 a.m. ET on January 10, 2022. 